Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1490001
European Journal of Endocrinology, Vol 149, Issue 1, 1-6
Copyright © 2003 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wasniewska, M
Right arrow Articles by Arrigo, T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wasniewska, M
Right arrow Articles by Arrigo, T

Articles

In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first Year of life irrespective of other variables related to treatment

M Wasniewska, F De Luca, A Cassio, N Oggiaro, P Gianino, M Delvecchio, R Aiazzi, V Stoppioni, F Lombardo, MF Messina, M Valenzise, and T Arrigo

Department of Pediatrics, University of Messina, Italy. wasniewska@yahoo.it

OBJECTIVE: To evaluate in a cohort of infants with congenital hypothyroidism (CH): (a) the frequency of bone maturation (BM) retardation at birth and (b) whether BM delay at birth may be considered as a tool to make a prognosis of psychomotor status at the age of 1 Year, irrespective of other variables related to treatment. DESIGN: BM at birth, CH severity and developmental quotient (DQ) at the age of 1 Year were retrospectively evaluated in 192 CH infants selected by the following inclusion criteria: (a) gestation age ranging between 38 and 42 weeks; (b) onset of therapy within the first Month of life; (c) initial thyroxine (l-T(4)) dosage ranging from 10 to 12 microg/kg/day; (d) normalization of serum thyrotropin (TSH) levels before the age of 3 Months; (e) Monthly adjustments of l-T(4) dose during the first Year of life with serum TSH levels ranging from 0.5 to 4 mIU/l; (f) no major diseases and/or physical handicaps associated with CH; (g) availability of both thyroid scanning and knee X-rays at the time of treatment initiation; (h) availability of DQ assessment at an average age of 12 Months. METHODS: BM was considered normal if the distal femur bony nucleus diameter exceeded 3 mm (group A) or retarded if either this nucleus was absent (subgroup B1) or its diameter was <3 mm (subgroup B2). DQ was evaluated with the Brunet-Lezine test. RESULTS: In 44.3% of cases BM was either delayed (23.5%) or severely delayed (20.8%). The risk of BM retardation was higher in the patients with athyreosis than in the remaining patients (41/57 vs 44/135, chi(2)=25.13, P<0.005). BM-retarded infants showed a more severe biochemical picture of CH at birth and a lower DQ at the age of one Year compared with the group A patients. If compared with infants of subgroup B2 those of subgroup B1 exhibited significantly lower T(4) levels at birth and a more frequent association with athyreosis (70.0 vs 30.0%; chi(2)=7.49, P<0.01), whereas DQ was superimposable in both subgroups. CONCLUSIONS: (a) BM at birth is delayed in almost half of CH patients and (b) CH severity per se can affect DQ at the age of 1 Year irrespective of other variables related to therapy.


This article has been cited by other articles:


Home page
CLIN PEDIATRHome page
M. Nakamizo, S.-i. Toyabe, T. Asami, and K. Akazawa
Mental Development of Infants With Congenital Hypothyroidism: A Longitudinal Study
Clinical Pediatrics, January 1, 2007; 46(1): 53 - 58.
[Abstract] [PDF]


Home page
Eur J EndocrinolHome page
S. Pagani, C. Meazza, P. Travaglino, F. De Benedetti, C. Tinelli, and M. Bozzola
Serum cytokine levels in GH-deficient children during substitutive GH therapy
Eur. J. Endocrinol., February 1, 2005; 152(2): 207 - 210.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
P. Florio, P. Ciarmela, F. M Reis, P. Toti, L. Galleri, R. Santopietro, E Tiso, P. Tosi, and F. Petraglia
Inhibin {alpha}-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma
Eur. J. Endocrinol., February 1, 2005; 152(2): 277 - 284.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 European Society of Endocrinology.